Metoprolol Succinate Extended-Release Tablets

Type of Posting: Notice of Intent to Revise
Posting Date: 26–Jan–2018, revised 12–Feb–2018¹
Targeted Official Date: To Be Determined, Revision Bulletin
Expert Committee: Chemical Medicines Monographs 2

In accordance with section 7.04 (c) of the 2015–2020 Rules and Procedures of the Council of Experts and the Pending Monograph Guideline, this is to provide notice that the Chemical Medicines Monographs 2 Expert Committee intends to revise the Metoprolol Succinate Extended-Release Tablets monograph.

Based on the supporting documents received from a manufacturer awaiting FDA approval, the Expert Committee proposes to add Test 3 in Dissolution section of the monograph.

The proposed revision is contingent on FDA approval of a product that meets the proposed monograph². The proposed revision will be published as a Revision Bulletin and an official date will be assigned to coincide as closely as possible with the FDA approval of the associated product.

Should you have any questions, please contact Donald Min, Ph.D., Senior Scientific Liaison to the Chemical Medicines Monographs 2 Expert Committee (301–230–7457 or ddm@usp.org)

¹ The notice was revised on February 12, 2018 to make editorial changes and add footnote. No changes were made to the content of the proposed monograph.

² This text is not the official version of a USP–NF monograph and may not reflect the full and accurate contents of the monograph in effect today. Please refer to the current edition of the USP–NF for official text.

USP provides this text as a courtesy to indicate changes that we anticipate will be made official once the product subject to this pending monograph receives FDA approval. Once FDA approval is granted, the official monograph will include the changes indicated herein and any changes indicated in the product’s final approval, combined with the text of the monograph as effective on the date of approval.
Metoprolol Succinate Extended-Release Tablets

Definition
Metoprolol Succinate Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of metoprolol succinate \( \left( \text{C}_{15}\text{H}_{25}\text{NO}_3 \right)_2 \cdot \text{C}_4\text{H}_6\text{O}_4 \).

Identification
- A. Infrared Absorption (197K)
  Sample solution: Equivalent to 200 mg of metoprolol succinate from NLT 1 Tablet in a stopped centrifuge tube. Add 40 mL of pH 6.8 phosphate buffer (see Reagents, Indicators, and Solutions—Buffer Solutions) and 40 mL of methylene chloride, and shake for 5 min. Centrifuge, filter, and use the aqueous phase as the Sample solution.
  Sample: Transfer 3 mL of the Sample solution to a separator. Add 2 mL of ammonium hydroxide, and extract with 20 mL of methylene chloride. Filter the methylene chloride phase. Grind 1 mL of the filtrate with 300 mg of potassium bromide, dry in a current of warm air, and prepare a disk.
  Acceptance criteria: The IR spectrum of the Sample exhibits maxima only at the same wavelengths as those obtained from a similar preparation of USP Metoprolol Succinate RS (presence of metoprolol).

- B. Infrared Absorption (197K)
  Sample: Transfer 5 mL of the Sample solution prepared in Identification A to a glass-stoppered test tube. Add 2 mL of 5 N hydrochloric acid, and extract with 5 mL of ether. Filter the ether phase. Grind 2 mL of the filtrate with 300 mg of potassium bromide, dry in a current of warm air, and prepare a disk.
  Acceptance criteria: The IR spectrum of the Sample exhibits maxima only at the same wavelengths as those obtained from a similar preparation of succinic acid (presence of succinate).

Add the following:
- C. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay/AUSP41

Assay

Change to read:

- Procedure
  Buffer: Mix 50 mL of 1 M monobasic sodium phosphate and 8.0 mL of 1 M phosphoric acid, and dilute with water to 1000 mL. If necessary, adjust with 1 M monobasic potassium phosphate or 1 M phosphoric acid to a pH of 3.0.
  Mobile phase: Acetonitrile and Buffer (250:750)
  Standard solution: 0.05 mg/mL of USP Metoprolol Succinate RS in Mobile phase
  Sample stock solution: Nominally 1 mg/mL of metoprolol succinate prepared as follows. Transfer a suitable number of Tablets to a suitable volumetric flask, add about 5 mL of water, and allow the Tablets to disintegrate. Add a volume of alcohol to fill 30% of the flask volume, and shake for 30 min. Add a portion of 0.1 N hydrochloric acid to fill 50% of the flask volume, and shake for an additional 30 min. Dilute with 0.1 N hydrochloric acid to volume. Filter, and discard the first 10 mL of the filtrate.

Sample solution: Nominally 0.05 mg/mL of metoprolol succinate from the Sample stock solution in Mobile phase

Chromatographic System
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 280 nm
Column: 4-mm × 12.5-cm; 5-µm packing L1
Flow rate: 1 mL/min
Injection volume: 40 µL

System suitability
Sample: Standard solution
Suitability requirements
Acceptance criteria:
- Tailing factor: NMT 2.0
- Relative standard deviation: NMT 2.0%
- Assay obtained in the System suitability test obeys the acceptance criteria in Table 1.

Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of the labeled amount of metoprolol succinate \( \left( \text{C}_{15}\text{H}_{25}\text{NO}_3 \right)_2 \cdot \text{C}_4\text{H}_6\text{O}_4 \) in the portion of Tablets taken:

\[
\text{Result} = \frac{r_U}{r_S} \times \left( \frac{C_S}{C_U} \right) \times 100
\]

\( r_U \) = peak response of metoprolol from the Sample solution
\( r_S \) = peak response of metoprolol from the Standard solution
\( C_S \) = concentration of USP Metoprolol Succinate RS in the Standard solution (mg/mL)
\( C_U \) = nominal concentration of metoprolol succinate in the Sample solution (mg/mL)

Acceptance criteria: 90.0%–110.0%

Performance Tests

Change to read:

- Dissolution (711)
  Test 1
  Medium: pH 6.8 phosphate buffer (see Reagents, Indicators, and Solutions—Buffer Solutions), 500 mL
  Apparatus 2: 50 rpm
  Times: 1, 4, 8, and 20 h
  Buffer, Mobile phase, and Standard solution: Prepare as directed in the Assay/AUSP41
  Analysis: Proceed as directed in the Assay/AUSP41 except use 5.0 mL of a filtered portion of the solution under test as the Sample solution, and use Medium as the blank, in comparison with a Standard solution with a known concentration of USP Metoprolol Succinate RS in the same Medium.
  Acceptance criteria: See Table 1.

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NMT 25</td>
</tr>
<tr>
<td>4</td>
<td>20–40</td>
</tr>
<tr>
<td>8</td>
<td>40–60</td>
</tr>
<tr>
<td>20</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

The percentages of the labeled amount of metoprolol succinate \( \left( \text{C}_{15}\text{H}_{25}\text{NO}_3 \right)_2 \cdot \text{C}_4\text{H}_6\text{O}_4 \) dissolved at the times specified conform to Dissolution (711), Acceptance Table 2.

Test 2: If the product complies with this test, the labeling indicates that the product meets USP Dissolution Test 2.

Medium: Simulated gastric fluid without enzyme, pH 1.2; 500 mL

© The United States Pharmacopeial Convention All Rights Reserved.
Metoprolol

Apparatus 2: 75 rpm
Times: 1, 4, 8, and 20 h
Buffer: 1 M monobasic sodium phosphate, 1 M phosphoric acid, and water (50:8:924). If necessary, adjust with 1 M monobasic sodium phosphate or 1 M phosphoric acid to a pH of 3.0.

Mobile phase: Acetonitrile and Buffer (250:750)

Standard solution: Prepare a solution of USP Metoprolol Succinate RS in Medium as directed in Table 2.

Table 2

<table>
<thead>
<tr>
<th>Tablet Strength (mg, as metoprolol succinate)</th>
<th>Concentration (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>0.380</td>
</tr>
<tr>
<td>100</td>
<td>0.190</td>
</tr>
<tr>
<td>50</td>
<td>0.095</td>
</tr>
<tr>
<td>25</td>
<td>0.048</td>
</tr>
</tbody>
</table>

Sample solution: Pass the solution under test through a suitable filter.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 280 nm
Column: 4.0-mm × 12.5-cm; 4-µm packing L7
Flow rate: 1 mL/min
Injection volume: See Table 3.

Table 3

<table>
<thead>
<tr>
<th>Tablet Strength (mg, as metoprolol succinate)</th>
<th>Volume (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>40</td>
</tr>
<tr>
<td>50</td>
<td>20</td>
</tr>
<tr>
<td>100</td>
<td>10</td>
</tr>
<tr>
<td>200</td>
<td>5</td>
</tr>
</tbody>
</table>

System suitability
Sample: Standard solution
Suitability requirements
Column efficiency: NLT 1500 theoretical plates
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Standard solution and Sample solution
Calculate the concentration (Ci) of metoprol succinate dissolved in Medium at each time point (i):

\[ \text{Result} = \left( \frac{r_i}{r_s} \right) \times C_i \]

ri = peak response of metoprol from the Sample solution
rs = peak response of metoprol from the Standard solution
Ci = concentration of USP Metoprol Succinate RS in the Standard solution (mg/mL)

Calculate the percentage of the labeled amount of metoprol succinate \((\text{Ci} \times \text{H}_2\text{NO}_3\text{)} \cdot \text{C}_4\text{H}_6\text{O}_4)\) dissolved (Qi), at each time point (i):

\[ \text{Result}_1 = C_i \times V \times \left(1/100 \times (1-L) \times 100\right) \]

\[ \text{Result}_2 = \left[ (C_i \times V) / 2 \right] \times (1/L) \times 100 \]

\[ \text{Result}_3 = \left[ (C_i \times V) / 3 \right] \times (1/L) \times 100 \]

\[ \text{Result}_4 = \left[ (C_i \times V) / 3 \right] \times (1/L) \times 100 \]

Ci = concentration of metoprol succinate in the portion of sample withdrawn at time point (i) (mg/mL)
V = volume of Medium, 500 mL
L = label claim (mg/Tablet)
V3 = volume of the Sample solution withdrawn from the Medium (mL)

Tolerances: See Table 4.

Table 4

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (b)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>NMT 20</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>20–40</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>55–85</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

The percentages of the labeled amount of metoprol succinate \((\text{Ci} \times \text{H}_2\text{NO}_3\text{)} \cdot \text{C}_4\text{H}_6\text{O}_4)\) dissolved at the times specified conform to Dissolution (711), Acceptance Table 2.

Test 3: If the product complies with this test, the labeling indicates that the product meets USP Dissolution Test 3.

Medium: pH 6.8 phosphate buffer (dissolve 6.8 g of monobasic potassium phosphate and 0.91 g of sodium hydroxide in 1000 mL of water; adjust with 1 N sodium hydroxide to a pH of 6.8); 500 mL

Apparatus 2: 50 rpm
Times: 1, 4, 8, and 24 h
Buffer: Transfer 50 mL of 1 M monobasic sodium phosphate and 8 mL of 1 M phosphoric acid in a 1000-mL volumetric flask. Dilute with water to the volume. If necessary, adjust with 1 M monobasic sodium phosphate or 1 M phosphoric acid to a pH of 3.0.

Mobile phase: Acetonitrile and Buffer (25:75)

Standard solution: 0.05 mg/mL of USP Metoprol Succinate RS in Medium
Sample solution: Withdraw a 10-mL aliquot at each time point. Pass the solution through a suitable filter, Dilute with Medium to a concentration similar to that of the Standard solution, if needed. Replace the portion withdrawn with an equal volume of Medium except for the last time point.

Chromatographic system
(See Chromatography (621), System Suitability.)
Metoprolol

IMPUtVES

Change to read:

▲ ORGANIC IMPURITIES

Buffer: 1.15 mL of phosphoric acid in 2 L of water.
Add 2.6 g of sodium dodecyl sulfate. Sonicate to dissolve.

Solution A: Methanol and Buffer (30:70)
Solution B: Acetonitrile and Buffer (75:25)
Mobile phase: See Table 6 (TBD)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solution A (%)</th>
<th>Solution B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>20</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>25</td>
<td>40</td>
<td>60</td>
</tr>
<tr>
<td>30</td>
<td>35</td>
<td>65</td>
</tr>
<tr>
<td>35</td>
<td>35</td>
<td>65</td>
</tr>
<tr>
<td>37</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>50</td>
<td>65</td>
<td>35</td>
</tr>
</tbody>
</table>

Diluent: Acetonitrile and Buffer (40:60)

System suitability solution: 3 μg/mL of USP Metoprolol Related Compound A RS and 1 mg/mL of USP Metoprolol Succinate RS in Diluent

Sensitivity solution: 0.5 μg/mL of USP Metoprolol Succinate RS from Standard solution in Diluent

Solution: Nominally 1 mg/mL of metoprolol succinate from Tablets prepared as follows. Transfer a portion of finely powdered Tablets (NLT 20), equivalent to 50 mg of metoprolol succinate, to a 50-mL volumetric flask. Add Diluent to fill 60% of the flask volume, and sonicate for 30 min with intermittent shaking. Dilute with Diluent to volume. Pass the solution through a suitable filter of 0.45-μm pore size.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 223 nm
Column: 4.6-mm × 15-cm; 5-μm packing L1
Column temperature: 30°
Flow rate: 1 mL/min
Injection volume: 10 μL

System suitability
Samples: System suitability solution, Standard solution, and Sensitivity solution
Suitability requirements
Resolution: NLT 2.0 between metoprolol related compound A and metoprolol, System suitability solution
Relative standard deviation: NMT 5.0%, Standard solution
Signal-to-noise ratio: NLT 10, Sensitivity solution

Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of each unspecified degradation product in the portion of Tablets taken taken:

Result = \( \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_i}{C_S} \right) \times 100 \)

\( r_U \) = peak response of each unspecified degradation product from the Sample solution
\( r_S \) = peak response of metoprolol from the Standard solution
**ADDENDUM** to read: **Metoprolol**

- **Acceptance criteria:** See Table [7](#) Reporting threshold: 0.05%.

<table>
<thead>
<tr>
<th>Name</th>
<th>Relative Retention Time</th>
<th>Acceptance Criteria, NMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Succinic acid&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.1</td>
<td>—</td>
</tr>
<tr>
<td>Metoprolol related compound A</td>
<td>0.83</td>
<td>—</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>1.0</td>
<td>—</td>
</tr>
<tr>
<td>Any unspecified degradation product</td>
<td>—</td>
<td>0.20</td>
</tr>
<tr>
<td>Total impurities</td>
<td>—</td>
<td>0.75</td>
</tr>
</tbody>
</table>

<sup>a</sup> Counter ion included for identification only.

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in tight containers, and store at controlled room temperature.
- **LABELING:** Label it to indicate the content of metoprolol succinate and its equivalent, expressed as metoprolol succinate [(C_{15}H_{25}NO_{3})_{2} · C_{4}H_{6}O_{6}]. When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 is not used.

Change to read:

- **USP REFERENCE STANDARDS** *(11)*
  - USP Metoprolol Related Compound A RS
  - 1-Ethylamino-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol:
    - C_{14}H_{23}NO_{3} 253.34<sup>USP41</sup>
    - USP Metoprolol Succinate RS